重药控股涨4.36%，成交额1.18亿元，主力资金净流入1394.26万元

Group 1 - The core viewpoint of the news is that Chongqing Pharmaceutical Holdings has shown a significant increase in stock price and positive financial performance indicators, indicating potential growth in the pharmaceutical distribution sector [1][2]. Group 2 - As of January 9, the stock price of Chongqing Pharmaceutical Holdings rose by 4.36% to 6.22 CNY per share, with a total market capitalization of 10.749 billion CNY [1]. - The company has seen a year-to-date stock price increase of 6.87%, with a 20-day increase of 6.14% and a 60-day increase of 18.70% [1]. - The main business revenue composition includes 81.74% from pharmaceuticals, 16.71% from medical devices, and 1.54% from other sources [1]. Group 3 - For the period from January to September 2025, Chongqing Pharmaceutical Holdings achieved a revenue of 62.211 billion CNY, representing a year-on-year growth of 4.22%, while the net profit attributable to shareholders increased by 31.41% to 384 million CNY [2]. - The company has distributed a total of 864 million CNY in dividends since its A-share listing, with 294 million CNY distributed in the last three years [3]. Group 4 - As of September 30, 2025, the number of shareholders for Chongqing Pharmaceutical Holdings decreased by 4.05% to 42,000, while the average circulating shares per person increased by 4.22% to 41,112 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.091 million shares, an increase of 851,000 shares compared to the previous period [3].